MedTrace Logo

Long Term Follow-up Study for Subjects Administered CLBR001

NCT06882317 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2026-04-08

No results posted yet for this study

Summary

The goal of this Long Term Follow-Up observational study is to monitor subjects who have received CLBR001, a lentiviral vector based chimeric antigen receptor, for delayed adverse events that may be associated with human gene therapies.

Participants will be followed for 15 years post-gene therapy administration date for safety and efficacy.

Conditions

  • Long Term Follow-Up

Interventions

OTHER

Long Term Follow-Up

No intervention is administered on this study. Subjects who have received CLBR001 autologous CAR-T cells in a primary Calibr treatment trial will be followed long term in line with FDA guidance.

Sponsors & Collaborators

  • Calibr, a division of Scripps Research

    lead OTHER

Principal Investigators

  • Chief Medical Officer · Calibr-Skaggs Institute for Innovative Medicines

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-28
Primary Completion
2044-02-29
Completion
2044-02-29

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06882317 on ClinicalTrials.gov